Type 2 diabetes mellitus is a growing health problem, characterized by insulin resistance progressing to beta cell dysfunction and insulin deficiency, most of these patients will need intensification of treatment and initiation of insulin to delay or prevent diabetic complications. Glycemic control is the most important aspect of management, and in reducing morbidity and mortality of the diseases. Control of plasma glucose in patients with diabetes can be assessed by HbA1c, FPG, PPG, but still HbA1c% remains the gold standard for assessment of glycemic control and follow up of diabetic patients. The aim of this study is to assess HbA1c% in patients on oral anti-diabetic drugs, with poor glycemic control before and after adding basal insulin, with titration of the dose of insulin depending on fasting blood sugar. 82 patients with uncontrolled type 2 diabetes (43.9% male, 56.1% female), with HbA1c more than 9%, on two types of oral diabetic medication or more, were started on basal insulin (glargine, lantus) and followed for three to six months. Overall 82 patients with type 2 diabetes mellitus were included in the study. The mean age of the study population was 58.4 years, the mean duration of the disease range was 13.4 years. All patients with HbA1c more than 9%, without organ failure, were included in the study. The mean HbA1c overall had decreased from mean of 11.15% before starting basal insulin to the mean of 8.43% within 3 to 6 month, after initiating basal insulin, this difference was significant at p < 0.001. There was no adverse effect on this medication in any of the study group. The addition of basal insulin to oral anti-diabetic medication in uncontrolled insulin-naïve type 2 diabetic patients resulted in significant improvement of glycemic control, with improved HbA1c level, without adverse effects.
References
[1]
Sanlioglu, A.D., et al. (2013) Clinical Utility of Insulin and Insulin Analogs. Islets, 5, 67-78. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4204021/ https://doi.org/10.4161/isl.24590
[2]
UK Prospective Diabetes Study Group (1995) UK Prospective Diabetes Study 16: Overview of 6 Years’ Therapy of Type II Diabetes: A Progressive Disease. Diabetes, 44, 1249-1258. https://doi.org/10.2337/diab.44.11.1249
[3]
Belay, E., et al. (2015) Correlation of Fasting and Postprandial Plasma Glucose with HbA1c in Assessing Glycemic Control; Systematic Review and Meta-Analysis. Archives of Public Health, 73, Article No. 43. https://doi.org/10.1186/s13690-015-0088-6
[4]
Rubino, A., et al. (2007) Delayed Initiation of Subcutaneous Insulin Therapy after Failure of Oral Glucose-Lowering Agents in Patients with Type 2 Diabetes: A Population-Based Analysis in the UK. Diabetic Medicine, 24, 1412-1418. https://doi.org/10.1111/j.1464-5491.2007.02279.x
[5]
Arnolds, S., et al. (2013) Common Standards of Basal Insulin Titration in T2DM. Journal of Diabetes Science and Technology, 7, 771-788. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3869146/ https://doi.org/10.1177/193229681300700323
[6]
Rosenstock, J. (2004) Basal Insulin Supplementation in Type 2 Diabetes: Refining the Tactics. The American Journal of Medicine, 116, 10S-16S. https://doi.org/10.1016/j.amjmed.2003.12.004
[7]
Lee, B.-W., et al. (2017) Insulin Therapy for Adult Patients with Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association, 2017. The Korean Journal of Internal Medicine, 32, 967-973. https://doi.org/10.3904/kjim.2017.314
[8]
Vora, J. et al. (2015) Intensifying Insulin Regimen after Basal Insulin Optimization in Adults with Type 2 Diabetes: A 24-Week, Randomized, Open-Label Trial Comparing Insulin Glargine Plus Insulin Glulisine with Biphasic Insulin Aspart (LanScape). Diabetes, Obesity & Metabolism, 17, 1133-1141. http://www.ncbi.nlm.nih.gov/pubmed/26085028 https://doi.org/10.1111/dom.12528
[9]
Laakso, M. (1999) Benefits of Strict Glucose and Blood Pressure Control in Type 2 Diabetes. Circulation, 99, 461-462. http://circ.ahajournals.org/content/99/4/461 https://doi.org/10.1161/01.CIR.99.4.461
